Evidence method
Level · gp.fundamentals.debt_to_revenue
264.48% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Sep 30, 2018
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-18-057627General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.71% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
16.41% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
5.27% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
78.90% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
69.22% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
19.95% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
9.20% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.49% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 279.47%
- Current
- 264.48%
- Delta
- -14.99%
- Previous
- 2.30%
- Current
- 2.71%
- Delta
- 0.41%
- Previous
- 18.18%
- Current
- 16.41%
- Delta
- -1.77%
- Previous
- 5.59%
- Current
- 5.27%
- Delta
- -0.32%
- Previous
- 79.88%
- Current
- 78.90%
- Delta
- -0.97%
- Previous
- 64.90%
- Current
- 69.22%
- Delta
- 4.33%
- Previous
- 15.37%
- Current
- 19.95%
- Delta
- 4.58%
- Previous
- 10.87%
- Current
- 9.20%
- Delta
- -1.66%
- Previous
- 3.73%
- Current
- 3.49%
- Delta
- -0.24%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP MARGIN_INCREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.